Psoriasis Therapeutics-Global Market Status and Trend Report 2016-2026

Table of Contents

Chapter 1 Overview of Psoriasis Therapeutics

• 1.1 Definition of Psoriasis Therapeutics in This Report
• 1.2 Commercial Types of Psoriasis Therapeutics
  • 1.2.1 TNF Inhibitors
  • 1.2.2 PDE4 Inhibitors
  • 1.2.3 Interleukin Blockers
  • 1.2.4 Others
• 1.3 Downstream Application of Psoriasis Therapeutics
  • 1.3.1 Oral
  • 1.3.2 Parenteral
  • 1.3.3 Topical
• 1.4 Development History of Psoriasis Therapeutics
• 1.5 Market Status and Trend of Psoriasis Therapeutics 2016-2026
  • 1.5.1 Global Psoriasis Therapeutics Market Status and Trend 2016-2026
  • 1.5.2 Regional Psoriasis Therapeutics Market Status and Trend 2016-2026

Chapter 2 Global Market Status and Forecast by Regions

• 2.1 Market Development of Psoriasis Therapeutics 2016-2021
• 2.2 Production Market of Psoriasis Therapeutics by Regions
  • 2.2.1 Production Volume of Psoriasis Therapeutics by Regions
  • 2.2.2 Production Value of Psoriasis Therapeutics by Regions
• 2.3 Demand Market of Psoriasis Therapeutics by Regions
• 2.4 Production and Demand Status of Psoriasis Therapeutics by Regions
  • 2.4.1 Production and Demand Status of Psoriasis Therapeutics by Regions 2016-2021
  • 2.4.2 Import and Export Status of Psoriasis Therapeutics by Regions 2016-2021

Chapter 3 Global Market Status and Forecast by Types

• 3.1 Production Volume of Psoriasis Therapeutics by Types
• 3.2 Production Value of Psoriasis Therapeutics by Types
• 3.3 Market Forecast of Psoriasis Therapeutics by Types

Chapter 4 Global Market Status and Forecast by Downstream Industry

• 4.1 Demand Volume of Psoriasis Therapeutics by Downstream Industry
• 4.2 Market Forecast of Psoriasis Therapeutics by Downstream Industry

Chapter 5 Market Driving Factor Analysis of Psoriasis Therapeutics

• 5.1 Global Economy Situation and Trend Overview
• 5.2 Psoriasis Therapeutics Downstream Industry Situation and Trend Overview

Chapter 6 Psoriasis Therapeutics Market Competition Status by Major Manufacturers

• 6.1 Production Volume of Psoriasis Therapeutics by Major Manufacturers
• 6.2 Production Value of Psoriasis Therapeutics by Major Manufacturers
• 6.3 Basic Information of Psoriasis Therapeutics by Major Manufacturers
  • 6.3.1 Headquarters Location and Established Time of Psoriasis Therapeutics Major Manufacturer
  • 6.3.2 Employees and Revenue Level of Psoriasis Therapeutics Major Manufacturer
• 6.4 Market Competition News and Trend
  • 6.4.1 Merger, Consolidation or Acquisition News
  • 6.4.2 Investment or Disinvestment News
  • 6.4.3 New Product Development and Launch

Chapter 7 Psoriasis Therapeutics Major Manufacturers Introduction and Market Data

• 7.1 Astellas Pharma Inc.
  • 7.1.1 Company profile
  • 7.1.2 Representative Psoriasis Therapeutics Product
  • 7.1.3 Psoriasis Therapeutics Sales, Revenue, Price and Gross Margin of Astellas Pharma Inc.
• 7.2 AstraZeneca plc
  • 7.2.1 Company profile
  • 7.2.2 Representative Psoriasis Therapeutics Product
  • 7.2.3 Psoriasis Therapeutics Sales, Revenue, Price and Gross Margin of AstraZeneca plc
• 7.3 Boehringer Ingelheim GmbH
  • 7.3.1 Company profile
  • 7.3.2 Representative Psoriasis Therapeutics Product
  • 7.3.3 Psoriasis Therapeutics Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim GmbH
• 7.4 F. Hofffmann-La Roche
  • 7.4.1 Company profile
  • 7.4.2 Representative Psoriasis Therapeutics Product
  • 7.4.3 Psoriasis Therapeutics Sales, Revenue, Price and Gross Margin of F. Hofffmann-La Roche
• 7.5 GlaxoSmithKline plc
  • 7.5.1 Company profile
  • 7.5.2 Representative Psoriasis Therapeutics Product
  • 7.5.3 Psoriasis Therapeutics Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc
• 7.6 Merck & Co., Inc.
  • 7.6.1 Company profile
  • 7.6.2 Representative Psoriasis Therapeutics Product
  • 7.6.3 Psoriasis Therapeutics Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
• 7.7 Valeant Pharmaceuticals International, Inc.
  • 7.7.1 Company profile
  • 7.7.2 Representative Psoriasis Therapeutics Product
  • 7.7.3 Psoriasis Therapeutics Sales, Revenue, Price and Gross Margin of Valeant Pharmaceuticals International, Inc.
• 7.8 Biocon Limited
  • 7.8.1 Company profile
  • 7.8.2 Representative Psoriasis Therapeutics Product
  • 7.8.3 Psoriasis Therapeutics Sales, Revenue, Price and Gross Margin of Biocon Limited
• 7.9 Eli Lilly and Company
  • 7.9.1 Company profile
  • 7.9.2 Representative Psoriasis Therapeutics Product
  • 7.9.3 Psoriasis Therapeutics Sales, Revenue, Price and Gross Margin of Eli Lilly and Company
• 7.10 G & W Laboratories Inc.
  • 7.10.1 Company profile
  • 7.10.2 Representative Psoriasis Therapeutics Product
  • 7.10.3 Psoriasis Therapeutics Sales, Revenue, Price and Gross Margin of G & W Laboratories Inc.

Chapter 8 Upstream and Downstream Market Analysis of Psoriasis Therapeutics

• 8.1 Industry Chain of Psoriasis Therapeutics
• 8.2 Upstream Market and Representative Companies Analysis
• 8.3 Downstream Market and Representative Companies Analysis

Chapter 9 Cost and Gross Margin Analysis of Psoriasis Therapeutics

• 9.1 Cost Structure Analysis of Psoriasis Therapeutics
• 9.2 Raw Materials Cost Analysis of Psoriasis Therapeutics
• 9.3 Labor Cost Analysis of Psoriasis Therapeutics
• 9.4 Manufacturing Expenses Analysis of Psoriasis Therapeutics

Chapter 10 Marketing Status Analysis of Psoriasis Therapeutics

• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
  • 10.1.3 Marketing Channel Development Trend
• 10.2 Market Positioning
  • 10.2.1 Pricing Strategy
  • 10.2.2 Brand Strategy
  • 10.2.3 Target Client
• 10.3 Distributors/Traders List

Chapter 11 Report Conclusion

Chapter 12 Research Methodology and Reference

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources